Perfusion System Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The Perfusion System Market is expected to register a CAGR of 8.2% over the forecast period.

The pandemic has impacted the studied market. In spite of the high prevalence of cardiovascular and respiratory diseases, the majority of cardiac surgical procedures were postponed or canceled, and the number of organ donations and transplants decreased significantly due to the pandemic outbreak. As a result, during the pandemic, the market witnessed a slight drop in perfusion system sales. For instance, as per the press release by XVIVO Perfusion AB in March 2021, due to the COVID-19 pandemic, XVIVO Perfusion witnessed a decrease in demand for transplant products in 2020. This has had a detrimental influence on XVIVO Perfusion system sales in the first quarter of 2020. The company also said that the sales fell around 15.0% less than the previous year during the first quarter. Thus, owing to the reduced demand for perfusion systems, the market witnessed a slight adverse impact during the pandemic. However, with the resumption of surgical procedures, organ transplantation procedures, declining cases of COVID-19, and ease of restrictions, the market has started to gain traction. It is expected to continue the upward trend over the forecast period.

The rising demand for organ transplantation, an increase in the prevalence of cardiovascular and respiratory diseases, and rising initiatives by the government and various organizations to promote organ donations are the major factors propelling the market growth. For instance, as per the data published by the Health Resources and Services Administration in March 2022, about 40,000 organ transplants were performed in the United States in 2021. In addition, 26,670 kidney transplants and 9,236 live transplants were performed in 2021 in the United States. The perfusion system is one of the essential requirements for organ preservation and transplantation; thus increasing number of organ transplants is anticipated to increase the demand for perfusion system. In addition, there is a rising prevalence of cardiovascular and respiratory diseases across the globe is also boosting the demand for organ transplantation, which in turn propelling the market growth. For instance, according to the WHO 2021 factsheet, asthma is a major NCD affecting both children and adults. Globally, asthma affected more than 262.0 million people in 2021 and caused more than 461,000 deaths.

Furthermore, as per the research study published by the European Respiratory Society (ERS) published in 2021, ERS estimated that there were 36,580,965 Europeans with COPD, and the number is projected to reach 49,453,852 people by the year 2050. Thus, owing to the rising demand for organ transplantation and an increase in the prevalence of respiratory diseases, the market is expected to witness high growth. Moreover, rising product launches by the key market players are also anticipated to boost market growth. For instance, in December 2021, OrganOx, a manufacturer of normothermic machine perfusion (NMP), received premarket clearance (PMA) from the U.S. FDA for its metra system. The OrganOx metra is a fully automated NMP system that is used to preserve and transport donor livers for transplantation. Thus, owing to product launches and rising organ transplantation procedures, considerable market growth is expected over the forecast period.

However, the high cost of the devices and organ transplantation may restrain the market growth over the forecast period.

Perfusion System Market Trends

Kidney Segment is Anticipated to Witness Considerable Growth Over the Forecast Period

The rising prevalence of chronic kidney diseases is the major factor driving the growth of the market; for instance, as per the data released by the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) in 2021, kidney disease affected around 850.0 million people globally. The same source also reported that one in ten adults has Chronic Kidney Disease (CKD) globally. The global burden of CKD is continuously increasing and is projected to become the fifth most common cause of death globally by 2040. Thus, with the rising prevalence of chronic kidney diseases, the need for kidney transplants is expected to increase, thereby boosting segment growth.

Furthermore, according to the 2021 updates from the Global Observatory on Donation and Transplantation, in 2020, around 129,681 total organ transplants were done worldwide, with 31.70% of recipients having received a kidney transplant. Thus, an increase in the number of kidney transplants is also expected to boost segment growth over the forecast period. In addition, various strategies adopted by the market players, such as product launches, mergers, and acquisitions, partnerships, are also expected to propel the segment growth. For instance, in August 2021, CytoSorbents Corporation and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, launched the Aferetica's PerLife ex vivo organ perfusion system for a kidney transplant and CytoSorbents' PerSorb adsorber, which is based on the CytoSorbents ECOS-300CY sorbent technology and is designed to remove inflammatory mediators during ex vivo organ perfusion. Thus, owing to increasing cases of kidney diseases and product launches, the segment is expected to witness considerable growth over the forecast period.

North America is Expected to Witness Significant Market Growth Over the Forecast Period

The North America region is expected to witness considerable growth over the forecast period owing to rising technological advancements and the presence of better healthcare infrastructure. Furthermore, the rising prevalence of cardiovascular and respiratory diseases in the region increases the demand for perfusion systems. For instance, according to the CDC report published in July 2022, more than 20.1 million adults suffered from coronary artery diseases in 2021. The same source also reported that every year, around 805,000 Americans have a heart attack. Furthermore, as per the government of Canada, Chronic Obstructive Pulmonary Disease (COPD) affected more than 488,100 people in 2021, which was around 7.5% of the total population. Hence, owing to the rising prevalence of respiratory diseases and cardiovascular diseases, the North American region is expected to witness significant market growth.

Key product launches, high concentration of market players or manufacturer's presence, acquisitions & partnerships among major players, and the increasing burden of heart diseases in the United States are some of the factors driving the growth of the perfusion system market in the country. For instance, in January 2022, Pedra Technology, a privately held company, reported that the FDA has granted it a Breakthrough Device Designation for the periprocedural use of its Pedra Xauron Perfusion System in the treatment of critical limb ischemia (CLTI). Furthermore, according to the CDC report published in 2021, each year, heart disease costs the United States economy around USD 229.0 billion. Thus, owing to the product launches and the rising burden of heart diseases in the country, the market is expected to hold a significant market share over the forecast period.

Perfusion System Market Competitor Analysis

The Perfusion System Market is a consolidated market owing to the presence of a few major market players. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known, including Bridge to Life (Europe) Ltd., Organ Assist B.V., Organ Recovery Systems, Inc, OrganOx Limited, Paragonix Technologies, Inc., Preservation Solutions Inc, TransMedics, Inc., Waters Medical Systems LLC, and XVIVO Perfusion AB among others.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.